Last updated: 2026-09-09 04:53:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Black Diamond Therapeutics, Inc. (BDTX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2.10, with a market capitalisation of $121.80M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.60 to $4.94. This page covers its latest market performance, valuation, price trends and company information.
$121.80M | |
$2.09 | |
$46.25 | |
$1.18 | |
$2.12 | |
315.55K | |
1.18M | |
-- | |
$4.94 | |
$1.60 | |
-- | |
-- |
Black Diamond Therapeutics, Inc. (BDTX) last closed at $2.12 as of 2026-09-08 23:51:00, unchanged from the previous close of $2.12.
During the latest regular trading session, BDTX traded between $1.18 and $46.25, with a volume of 315.55K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Black Diamond Therapeutics, Inc. (BDTX) moved from $2.27 to $2.10, representing a decline of 7.71% ($0.17).
The stock traded between $2.02 and $2.32 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 535.03 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 14.8%
BDTX is currently trading at $2.10, placing it 14.8% of the way from its 52-week low of $1.60 to its 52-week high of $4.94. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 21 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Black Diamond Therapeutics, Inc. (BDTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.